2024-10-22 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company that develops, manufactures, and markets drugs for the treatment of HIV/AIDS, hepatitis B and C, and other infectious diseases.

**1. Performance & Relative Strength:**

* **Cumulative Return (GILD):** -10.65%
* **Cumulative Return (VOO):** 136.39%
* **Difference:** -147.04%
* **Relative Strength:** 5.51 (This means that GILD is currently performing at the 5.51st percentile of its historical performance relative to the S&P 500.)

**2. Recent Price Action:**

* **Closing Price:** $86.44
* **5-Day Moving Average:** $86.71
* **20-Day Moving Average:** $85.05
* **60-Day Moving Average:** $80.46

**3. Technical Indicators:**

* **RSI:** 61.07 (Above 50, indicating potential overbought conditions, but not overly concerning)
* **PPO:** -0.12 (Negative value indicates that the price is below its moving average, suggesting potential downward momentum)
* **Delta_Previous_Relative_Divergence:** -0.26 (Indicates a recent short-term downtrend in the stock's relative performance)
* **Expected Return:** 0.0% (This indicates that over the long term, the stock is expected to deliver similar returns to the S&P 500, with no anticipated outperformance.)

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

* **Most Recent Earnings:** The most recent earnings report for Q2 2024 showed an EPS of 1.29, exceeding analyst estimates of 1.15. Revenue was also slightly above expectations, coming in at 6.95B$.
* **Outlook:** Gilead's recent performance has been characterized by mixed results. While the most recent quarter showed positive earnings and revenue, the prior quarter showed significant losses. The company's future growth is expected to be driven by its new HIV drug, Biktarvy, as well as its focus on oncology and cell therapy. 

**5. News & Recent Issues:**

* **Recent Market Outlook for GILD:** The stock has been trading relatively flat in recent months, indicating a lack of strong bullish or bearish sentiment. 
* **Analyst Opinions and Performance Highlights:**  While some analysts maintain a bullish outlook, others have expressed concern about the company's dependence on a few key drugs and its potential for future competition. FINBOLD has reported that Gilead's recent earnings beat has led to a slight upward adjustment in price targets from some analysts. 

**6. Overall Analysis:**

Gilead Sciences Inc. (GILD) is currently facing a challenging market environment. While its recent earnings beat was a positive development, the stock has underperformed the broader market in recent years. Its performance is characterized by a volatile price action and a lack of strong long-term growth prospects. However, the company's strong presence in the HIV market and its investments in other areas, like oncology, offer some potential for future growth.  

**7.  Recommendations:** 

Given the current market conditions and the stock's lackluster performance, investors should adopt a cautious approach toward Gilead Sciences Inc. (GILD). The company's long-term prospects remain unclear, and its recent earnings performance has been mixed. Investors may consider holding their existing positions, but should avoid making any significant new purchases at this time. 
